<DOC>
	<DOC>NCT02799680</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficiency of allogeneic cluster of differentiation 33 (CD33)-directed chimeric antigen receptor modified T cells (CART-33) infusions in patients with relapsed / refractory acute myeloid leukemia (AML).</brief_summary>
	<brief_title>Allogeneic CART-33 for Relapsed/Refractory CD33+ AML</brief_title>
	<detailed_description>The relapsed and/or refractory AML patients will receive infusions of allogeneic CART-33 within 1 week after chemotherapy. The re-induction chemotherapy regimen was primarily idarubicin and cytarabine, and no graft-versus-host disease (GVHD) prevention was conducted pre- and post- therapy.</detailed_description>
	<criteria>Age ≥ 50 years Patient with relapsed and/or refractory CD33 positive acute myeloid leukemia (AML) Estimated life expectancy ≥ 12 weeks (according to investigator's judgment) Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 Previous treatment with investigational gene or cell therapy medicine products CD33 negative leukemia Any uncontrolled active medical disorder that would preclude participation as outlined Pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>CART</keyword>
	<keyword>AML</keyword>
</DOC>